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Percutaneous “Gluing” of SVG Aneurysm
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ailed prior renal transplant, a hereditary C4 deficiency, and
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upture risk of the expanding SVG aneurysm, to the cardiac
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thylene-vinyl alcohol copolymer was used to seal thestium of the graft aneurysm with successful occlusion of
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eported case of percutaneous injection of ethylene-vinyl
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